Key Players
Competitive Landscape
The Herceptin biosimilars market brings together integrated biologics developers and multinational drug manufacturers alongside commercialization partners and regional oncology companies. Integrated developers control clinical and manufacturing evidence while commercialization partners add tender access where direct sales organizations remain limited.
Company investment has moved toward subcutaneous delivery and broader regulated-market commercialization since 2025. Celltrion submitted its Herzuma SC application to the EMA in April 2026 after completing a pivotal comparative trial. EirGenix and Sandoz launched Herwenda in Slovakia during March 2026. Price remains material across competitive tenders but hospital systems first compare approval breadth with supply reliability and administration support.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Celltrion submitted Herzuma SC to the EMA in April 2026 after a pivotal trial and reported an expected administration time of about five minutes. | Hospital systems seek shorter administration without lowering the comparative evidence standard. | Trastuzumab competition is extending from intravenous price toward formulation choice. | Subcutaneous supply can support administration services and hospital conversion programs. |
| EirGenix and Sandoz launched the 150 mg Herwenda presentation in Slovakia during March 2026 as European commercialization moved beyond authorization. | European hospitals need additional approved trastuzumab choices with dependable regional supply. | Country launches are widening commercial coverage across the authorized European footprint. | Local tenders can support distributor coverage and recurring inventory contracts. |
| Shanghai Henlius received FDA approval for interchangeable pertuzumab biosimilar Poherdy in November 2025 for use with trastuzumab-based regimens. | Oncology teams need lower-cost access across trastuzumab and pertuzumab combination regimens. | HER2 biosimilar portfolios are expanding beyond single-molecule trastuzumab competition. | Combination-regimen contracting can extend revenue across adjacent HER2 products. |
Samsung Bioepis and Amgen compete through approved products while Pfizer, Organon and Teva add multinational commercialization and Biocon Biologics with Dr. Reddy's Laboratories retain direct or regional portfolios without separate 2025-2026 trastuzumab events.
Source: Future Market Insights. Herceptin Biosimilars Market and Biosimilars and Follow-on Biologics Market Reports (2026-2036).
Celltrion and Shanghai Henlius cover formulation development and adjacent HER2 biosimilars while Sandoz and Biocon Biologics add regulated-market commercialization and supply.
Who leads formulation development in the Herceptin biosimilars market?
Celltrion leads the reviewed group on formulation breadth after submitting Herzuma SC to the EMA in April 2026. Shanghai Henlius competes through HERCESSI and Poherdy across trastuzumab and pertuzumab pathways managed with regional partners.
Which suppliers have documented regulated-market approvals?
FDA records six approved trastuzumab biosimilars for the United States including Kanjinti and Trazimera alongside Ontruzant and Herzuma plus Ogivri and HERCESSI. EMA authorization records also cover Herwenda and Dazublys for HER2-positive breast or gastric cancer indications.
Which companies provide broader HER2 biosimilar portfolios?
Shanghai Henlius supplies trastuzumab through HERCESSI and pertuzumab through Poherdy across partner-led markets. Sandoz adds Herwenda commercialization and licensed pertuzumab candidate EG1206A while Celltrion combines intravenous Herzuma with a submitted subcutaneous formulation.
Which suppliers serve North America and Europe?
Amgen and Pfizer maintain direct trastuzumab commercialization across North America and Europe while Biocon Biologics and Organon serve both regions through owned or partner-led brands. Celltrion and Sandoz extend coverage through direct operations and regional commercialization agreements across regulated markets.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Celltrion Inc. | Global development with direct and partner commercialization | Herzuma intravenous supply and an EMA-submitted subcutaneous formulation dated April 2026. |
| Samsung Bioepis Co., Ltd. | Global development with partner-led commercialization | Ontruzant trastuzumab approvals with Organon-led commercialization across regulated markets. |
| Amgen Inc. | North America and Europe | Kanjinti intravenous trastuzumab for approved breast and gastric cancer indications. |
| Pfizer Inc. | North America and Europe | Trazimera intravenous trastuzumab across United States and European authorization routes. |
| Biocon Biologics Ltd. | Direct and partner-led advanced or emerging markets | Ogivri and Hertraz trastuzumab commercialization across North America plus Europe and emerging markets. |
| Sandoz Group AG | Europe and international markets | Herwenda commercialization and licensed pertuzumab candidate EG1206A with EirGenix manufacturing support. |
| Shanghai Henlius Biotech, Inc. | Global development through regional partners | HERCESSI trastuzumab and FDA-approved Poherdy pertuzumab across partner-led markets. |
| Organon & Co. | Global commercialization partner | Ontruzant commercialization across mature regulated markets under Samsung Bioepis development rights. |
| Teva Pharmaceutical Industries Ltd. | North American commercialization partner | Herzuma commercialization in the United States under its agreement with Celltrion. |
| Dr. Reddy's Laboratories Ltd. | India and selected emerging markets | Hervycta intravenous trastuzumab within an India-focused biologics portfolio. |
Research Methodology
The selected companies illustrate market structure rather than a ranking and each inclusion requires current evidence of trastuzumab or adjacent HER2 biosimilar activity. Regulator records establish approval status while company releases establish dated actions or commercial coverage across markets. Product approvals belong to the named holder or commercial entity and not automatically to the wider corporate group. FMI's 82.0% trastuzumab biosimilar share applies to the 2026 product category estimate within this report.
